Common asthma drug can reduce COVID hospitalizations by 90% — study | The Times of Israel
Asthma drug budesonide shortens recovery time in non-hospitalised patients with COVID-19 | University of Oxford
Asthma Treatments for COVID-19 - Asthma Australia
I was a 'perfect setup' to be fooled by Covid-19 - STAT
COVID 19 and asthma Our expert answers your questions | VCU Health
Inhaled Steroid Disappoints for COVID-19 | MedPage Today
Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial - The Lancet Respiratory Medicine
Young Covid-19 survivors warn they're still suffering | CNN
Inhaled Steroid for Early COVID-19 Passes Another Test | MedPage Today
Can asthma inhalers prevent COVID-19 hospitalisations? The STOIC Study - Prof Mona Bafadhel - YouTube
Inhaled steroids to be tested as a possible treatment for COVID-19 as part of PRINCIPLE trial | NIHR
Sterilization plan of the used metered dose inhalers (MDI) to avoid wastage amid COVID-19 pandemic drug shortage | Journal of Pharmaceutical Policy and Practice | Full Text
Montreal researchers testing potential COVID-19 treatment with steroid inhaler | CTV News
Critical inhaler medication shortage looms as coronavirus cases soar - ABC News
Move on from COVID? Child care disruptions continue
Second study confirms benefits of budesonide in early stages of COVID-19 | NIHR Oxford Biomedical Research Centre
My Teacher's Mask: Back To School During Covid-19: Puffer, Inga: 9798672844480: Amazon.com: Books
Is Asthma Tx a Breath of Fresh Air for Early COVID-19 Patients? | MedPage Today
Here's why people with allergic asthma are at lower COVID-19 risk | Science News
Impact of COVID-19 on people with asthma: a mixed methods analysis from a UK wide survey | BMJ Open Respiratory Research
Asthma drug may reduce risk of severe Covid if taken early – study | Coronavirus | The Guardian
Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial - The Lancet
